Mills & Reeve is excited to have advised F-star Therapeutics, a clinical-stage biopharmaceutical company focused on transforming the lives of patients with cancer through the development of innovative tetravalent bispecific (mAb2™) antibodies, in relation to its proposed merger with Spring Bank Pharmaceuticals, Inc (a company listed on Nasdaq).
The combined company will be headquartered out of F-star’s existing facilities in Cambridge (UK) and Cambridge (MA) following closing, anticipated to complete in the fourth quarter of 2020. It will help to drive further growth and development towards effective cancer treatments.
Eliot Forster, CEO of F-star, said: “We are thrilled to have been able to unite Spring Bank Pharmaceuticals and F-star Therapeutics to pursue our mission of creating the next generation of immunotherapies. We are truly excited about this opportunity that will allow us to further advance our pipeline of novel tetravalent bispecific antibodies; we believe they will be able to address the limitations of current therapies in the field of immuno-oncology. It will allow for huge advancements in the effective cancer treatments that can be developed”.
John Fitzpatrick, General Counsel of F-star, said: “A huge thanks to the team at Mills & Reeve for their hard work and support which was critical in enabling us to achieve this deal – their transactional and sector knowledge proved invaluable”.
James Fry, head of Mills & Reeve’s life sciences practice and F-star relationship partner, said: “We are delighted to have supported F-star on this strategic transaction. We’ve really enjoyed working with both the F-star and Mintz Levin teams to deliver this important milestone”.
This transaction was led by corporate partners Stephen Hamilton and Jonathan Greenwood with key support from Kristian Shearsby, Sofie de Pfeiffer, Tom Samuel and Emma Wilson. Mills & Reeve’s transaction team acted alongside F-Star’s US advisers Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
See more details of the deal here.